Role of 11-Beta-Hydroxysteroid Dehydrogenase-1 on Glucose Metabolism in Humans

The Integrated Carbohydrate Physiology and Translation Laboratory at Mayo Clinic was the first to establish the definitive role of the enzyme 11-beta-hydroxysteroid dehydrogenase-1 in extra-adrenal cortisol production in people with and without type 2 diabetes.

Dr. Ananda Basu and Dr. Rita Basu, with their research team and the help of Michael G. Sarr, M.D., an emeritus at Mayo Clinic, established that the liver is the primary site of this enzyme activity in people who are obese and undergoing bariatric surgery.

In addition, in experiments performed in conjunction with Alan D. Cherrington, Ph.D., of Vanderbilt University, the lab demonstrated that blockade of this enzyme activity reduces extra-adrenal cortisol production with concomitant lowering of endogenous glucose production and plasma glucose levels in an experimental dog model.

More studies are needed to test 11-beta-hydroxysteroid dehydrogenase-1 inhibitors for treatment of excess cortisol in the liver in humans.